Compare Novo Nordisk A/S (NVO) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ProShares Ultra Semiconductors — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while ProShares Ultra Semiconductors trades at $90.41. The key difference: Novo Nordisk A/S pays a 3.63% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | USD | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $71.70 | $113.53 |
52-Week Low | $35.29 | $39.58 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
USD trades at $83.24, up 1.19% with bearish technical signals from moving averages. Key support lies at $80 with resistance at $85. The company announced a $0.14 dividend for H1-2026, payable June 30, 2026. Recent news highlights include coverage of semiconductor sector volatility and earnings from various firms, though specific financials for USD are not detailed in the provided data.
The outlook remains cautious due to bearish technical indicators and limited fundamental data. Investment opportunity hinges on upcoming financial disclosures and sector performance, while risks include market volatility and reliance on broader economic conditions affecting semiconductor and related industries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
